Clinical Trials Logo

Filter by:
NCT ID: NCT05529810 Completed - Clinical trials for Acute Coronary Syndrome

Characteristics and Consequences of Coronary Angiograms Performed in Intensive Care Patients

Coro-ICU
Start date: May 30, 2022
Phase:
Study type: Observational

Coronary angiography is a key examination in the management of many patients hospitalized in intensive care units. The most frequent indication remains the performance of a gesture of unblocking of part of the coronary network in the context of an acute coronary syndrome (ACS) complicated by cardiogenic shock (CS) and/or cardiac arrest. cardio-respiratory (ACR). However, there are other indications in intensive care, in particular for diagnostic purposes. Given the lack of harmlessness of this procedure in itself and the consequences of intra-hospital transport outside intensive care units for patients who are sometimes very unstable, the risk-benefit balance before performing a coronary angiography requires always be properly assessed by the resuscitating physician.

NCT ID: NCT05529524 Recruiting - Follicular Lymphoma Clinical Trials

Signatures of Response and Resistance to Mosunetuzomab in Follicular Lymphomas (FL)

Start date: November 7, 2022
Phase:
Study type: Observational

Mosunetuzumab is a T-cell bispecific antibody targeting CD20 and CD3 aiming to redirect T cells to engage and eliminate malignant B cells. Bispecific antibodies (BsAb) are a promising treatment option which can induce long-term responses in refractory and relapsed B cell lymphoma patients. However, the factors determining the quality and duration of responses are poorly understood.

NCT ID: NCT05529485 Completed - Cataract Clinical Trials

Quantification of Factors Influencing Endothelial Damage During Phacoemulsification

PREDICSPILOT
Start date: January 12, 2022
Phase:
Study type: Observational

The aim of this study is to determine the principal factors that influence endothelial cell loss three month post cataract surgery. Methods: Multi center observational Cohort study, inclusion period from 12/01/2022 to 10/06/2022. One hundred and seventy-five eyes of hundred and four patients who have appointment for cataract surgical indication were included. The percentage of corneal endothelial cell loss was quantified using specular microscopy before and 3 months after the surgery. 14 variables (pre-operative and intra-operative) that could be associated to endothelial cell injury were selected. A bivariate analysis of relationship between these factors and endothelial cell loss at 3 months was performed by simple linear regression (Wilcoxon and Fischer tests). Multivariate analysis was performed by multiple linear regression in order to identify the factors independently related to endothelial cell loss.

NCT ID: NCT05529316 Suspended - Advanced Melanoma Clinical Trials

A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma

Start date: December 12, 2022
Phase: Phase 2
Study type: Interventional

This study is an open-label, 2-part, Phase 2, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetic profiles of botensilimab as monotherapy and in combination with balstilimab in participants with advanced cutaneous melanoma refractory to checkpoint inhibitor therapy.

NCT ID: NCT05529251 Recruiting - Seminoma Clinical Trials

De-escalation Study for Stage IIa/IIb < 3 cm Seminoma

EDEN
Start date: September 6, 2022
Phase: Phase 2
Study type: Interventional

Phase II, multicenter, prospective, randomized, non-comparative, de-escalation study. Patients with stage IIa/IIb < 3 cm seminoma histologically proved after orchiectomy will be included in the study and will receive 1 cycle of Etoposide Cisplatine (EP) chemotherapy. Patients with negative week-3 PET-scan after the EP cycle, will be randomized (1:1 ratio, stratification according to the disease stage (stage IIa versus IIb seminoma)) to receive either radiotherapy (RT) boost on lymph nodes or 1 cycle of carboplatin AUC7 chemotherapy. Patients with positive week-3 PET-scan will received 3 additional cycles of EP chemotherapy. In parallel, eligible patients scheduled to receive standard lombo-aortic RT will be registered in an observational cohort.

NCT ID: NCT05529199 Recruiting - Obesity, Abdominal Clinical Trials

Impact of Preoperative Hypocaloric Hyperproteinic Lipid Restricting Diet on Bariatric Surgery

LipiDiet
Start date: August 31, 2022
Phase:
Study type: Observational

Obesity is one of the greatest pandemics of the 21st century with 30 million new cases each year. In France each year, 60,000 bariatric surgery procedures are performed. Many preoperative diets have been proposed in the literature with some studies giving positive results. But these diets are often strict and can have adverse effects on metabolism. Very few studies have described the PSMF diet. The hypothesis would be that this diet is associated with a reduction in liver volume with a reduction in steatosis.

NCT ID: NCT05529186 Recruiting - Renal Disease Clinical Trials

Causes of Mortality in Kidney Transplant Recipients

Paradigme
Start date: March 14, 2022
Phase:
Study type: Observational

The causes of mortality in kidney transplant patients and the risk factors for mortality have been widely published. However, there is a high variability according to geographical areas and time. Recent studies suggest that the classical hierarchy of causes of mortality, i.e. the predominance of cardiovascular causes of death, could be overturned by the increase in infectious and cancer-related deaths. Investigators will try to highlight this paradigm shift and the related risk factors by studying two large French transplantation databases.

NCT ID: NCT05528952 Recruiting - Clinical trials for Hepatocellular Carcinoma

Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

TERTIO
Start date: September 27, 2022
Phase: Phase 2
Study type: Interventional

The TERTIO trial will propose to determine the clinical interest and immunological efficacy of a treatment combining the CD4 helper T-inducer cancer anti-telomerase vaccine (UCPVax) with anti-PD-L1 therapy (atezolizumab) and bevacizumab in unresectable HCC by evaluation of the objective response rate at 6 months (randomized phase II, 10 centers, 105 patients)

NCT ID: NCT05528926 Recruiting - Irritable Mood Clinical Trials

RESist Against Irritability Superiority Trial

RESIST
Start date: April 25, 2023
Phase: N/A
Study type: Interventional

Irritability is defined as developmentally inappropriate proneness to anger. Irritability is a symptom of several mental health conditions in children and adolescents such as attention deficit hyperactivity disorder (ADHD), oppositional defiant disorder (ODD), conduct disorder (CD), depressive disorders, anxiety disorders.Irritability has been associated with poor functional outcomes across the lifespan and was found to be specifically associated with concurrent and longitudinal emotional disorders, suicidality and impaired academic and socio-professional functioning. Children with high irritability also have distinct physiological profiles with hyper-reactivity to stress and perceived threats. Despite the high prevalence and health issues related to irritability, there is little treatment research on this topic. Developing evidence-based non-pharmacological treatment options for children suffering from severe, chronic irritability is therefore a particularly important target for clinical research.

NCT ID: NCT05528900 Recruiting - Clinical trials for Food Protein Induced Enterocolitis Syndrome (FPIES)

A Multicentre French Prospective Study of Children With Food Protein Induced Enterocolitis Syndrome in Its Acute Form

SEIPA-FPIES
Start date: March 31, 2023
Phase: N/A
Study type: Interventional

Food protein induced enterocolitis syndrome (FPIES), is a non-IgE mediated food allergy (FA) which seems to expand, and occurring in infancy. This disease is usually unknown by clinicians. In 2017, an international workgroup of American Academy of Allergy, Asthma and Immunology published clinical criteria to specify the diagnosis. However, there is a lack of information in literature for describe the evolution and atypical phenotypes. In addition, no prospective French series has been published to date. The aim of the study is to collect clinical features and allergy testing of children who have acute form of FPIES at diagnosis and during evolution during three years